CereVance completed enrollment of 341 participants in a Phase 3 trial testing solengepras, a non-dopaminergic GPR6 inhibitor for Parkinson's motor fluctuations. The drug targets OFF-time reduction through a mechanism distinct from conventional dopamine-based therapies, addressing a significant gap in current treatment options for advanced motor dysfunction.
Key Points
- 341-patient Phase 3 trial enrollment completed across four regions
- Non-dopaminergic mechanism designed to reduce dopamine-related adverse effects
- Primary endpoint: reduction in daily OFF-time versus placebo at 12 weeks
Longevity Analysis
Parkinson's disease progression fundamentally disrupts the coordination between motor control, energy production, and neurological signaling—systems that define functional independence in aging. Conventional dopaminergic therapies often create motor complications (dyskinesia, ON-OFF cycling) that worsen quality of life. A mechanism that reduces motor fluctuation without triggering dopamine-related side effects represents a meaningful shift in how advanced neurodegeneration might be managed. The completion of this trial and the capital secured position this approach as a potential option for extending functional motor capacity in patients who have exhausted or become limited by current standards of care.
Original published by LT Wire.